JP6219016B2 - トレプロスチニル一水和物 - Google Patents

トレプロスチニル一水和物 Download PDF

Info

Publication number
JP6219016B2
JP6219016B2 JP2011508505A JP2011508505A JP6219016B2 JP 6219016 B2 JP6219016 B2 JP 6219016B2 JP 2011508505 A JP2011508505 A JP 2011508505A JP 2011508505 A JP2011508505 A JP 2011508505A JP 6219016 B2 JP6219016 B2 JP 6219016B2
Authority
JP
Japan
Prior art keywords
treprostinil
monohydrate
solid
anhydrous
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011508505A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011519927A5 (enExample
JP2011519927A (ja
Inventor
ウォルシュ，デーヴィド・エイ
Original Assignee
ユナイテッド セラピューティクス コーポレーション
ユナイテッド セラピューティクス コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユナイテッド セラピューティクス コーポレーション, ユナイテッド セラピューティクス コーポレーション filed Critical ユナイテッド セラピューティクス コーポレーション
Publication of JP2011519927A publication Critical patent/JP2011519927A/ja
Publication of JP2011519927A5 publication Critical patent/JP2011519927A5/ja
Application granted granted Critical
Publication of JP6219016B2 publication Critical patent/JP6219016B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/487—Separation; Purification; Stabilisation; Use of additives by treatment giving rise to chemical modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/14—Benz[f]indenes; Hydrogenated benz[f]indenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2011508505A 2008-05-08 2009-05-07 トレプロスチニル一水和物 Active JP6219016B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5150908P 2008-05-08 2008-05-08
US61/051,509 2008-05-08
PCT/US2009/002818 WO2009137066A1 (en) 2008-05-08 2009-05-07 Treprostinil monohydrate

Publications (3)

Publication Number Publication Date
JP2011519927A JP2011519927A (ja) 2011-07-14
JP2011519927A5 JP2011519927A5 (enExample) 2017-09-07
JP6219016B2 true JP6219016B2 (ja) 2017-10-25

Family

ID=41037724

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011508505A Active JP6219016B2 (ja) 2008-05-08 2009-05-07 トレプロスチニル一水和物

Country Status (8)

Country Link
US (1) US8350079B2 (enExample)
EP (2) EP2300408B1 (enExample)
JP (1) JP6219016B2 (enExample)
KR (1) KR20110010753A (enExample)
CN (1) CN102015613B (enExample)
CA (1) CA2723540C (enExample)
ES (1) ES2575565T3 (enExample)
WO (1) WO2009137066A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2526534C (en) 2003-05-22 2011-07-12 United Therapeutics Corporation Compounds and methods for delivery of prostacyclin analogs
CN103274926B (zh) 2007-12-17 2016-08-10 联合治疗公司 一种制备Remodulin中的活性成分曲前列素的改良方法
JP5681276B2 (ja) 2010-03-15 2015-03-04 ユナイテッド セラピューティクス コーポレイション 肺高血圧症のための治療
WO2011153363A1 (en) 2010-06-03 2011-12-08 United Therapeutics Corporation Treprostinil production
EP2681204B1 (en) 2011-03-02 2016-04-27 United Therapeutics Corporation Synthesis of intermediate for treprostinil production
CN103193626B (zh) 2012-01-10 2016-05-11 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
CN103193627B (zh) * 2012-01-10 2016-04-20 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
EP2970091A4 (en) * 2013-03-14 2017-02-08 United Therapeutics Corporation Solid forms of treprostinil
JP2016516693A (ja) 2013-03-15 2016-06-09 ユナイテッド セラピューティクス コーポレイション トレプロスチニルの塩
CN105228451B (zh) 2013-03-25 2018-03-30 联合治疗公司 制备具有硫醇连接子和聚乙二醇化形式的前列环素化合物的方法
CN105407883A (zh) 2013-04-30 2016-03-16 联合治疗学有限公司 控释药物制剂
HRP20210351T1 (hr) 2013-10-25 2021-04-30 Insmed Incorporated Spojevi prostaciklina
JP2017517550A (ja) * 2014-06-13 2017-06-29 ユナイテッド セラピューティクス コーポレイション トレプロスチニル製剤
WO2016038532A1 (en) * 2014-09-09 2016-03-17 Mylan Laboratories Limited Amorphous treprostinil diethanolamine
HU231184B1 (hu) * 2014-10-08 2021-07-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Treprostinil-nátrium-monohidrát és eljárás ennek előállítására
CN107108427A (zh) 2014-10-20 2017-08-29 联合治疗学有限公司 用于制备前列环素衍生物的中间体的合成
US10343979B2 (en) 2014-11-18 2019-07-09 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
IL310250B2 (en) 2016-05-05 2025-09-01 Liquidia Tech Inc Terpostinil in dry powder form for the treatment of pulmonary hypertension
CA3038276A1 (en) 2016-09-26 2018-03-29 United Therapeutics Corporation Treprostinil prodrugs
EP3548010A1 (en) 2016-12-05 2019-10-09 Corsair Pharma, Inc. Dermal and transdermal administration of treprostinil and salts thereof
ES2976468T3 (es) 2018-09-18 2024-08-01 Lilly Co Eli Sal de treprostinil erbumina
CN114072136B (zh) 2019-04-29 2024-11-29 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
US12435023B2 (en) * 2019-05-21 2025-10-07 Shanghai Forefront Pharmceutical Co., Ltd. Crystal form of Treprostinil sodium salt and preparation method therefor
CN114616225A (zh) 2019-08-23 2022-06-10 联合治疗公司 曲前列环素前药
US11339110B2 (en) 2019-12-19 2022-05-24 Chirogate International Inc. Efficient crystallization process for preparing ultrapure Treprostinil and crystal prepared therefrom
WO2021211916A1 (en) 2020-04-17 2021-10-21 United Therapeutics Corporation Treprostinil for use in the treatment of intersitial lung disease
EP4161909A1 (en) 2020-06-09 2023-04-12 United Therapeutics Corporation Fumaryl diketopiperidine prodrugs of treprostinil
US11447440B2 (en) 2020-10-29 2022-09-20 Chirogate International Inc. Treprostinil monohydrate crystals and methods for preparation thereof
CN117062605A (zh) 2020-12-14 2023-11-14 联合治疗公司 使用曲前列环素前药治疗疾病的方法
CN117479946A (zh) 2021-03-03 2024-01-30 联合治疗公司 含曲前列环素及其前药并还包含(e)-3,6-双[4-(n-羰基-2-丙烯基)酰胺丁基]-2,5-二酮哌嗪(fdkp)的干粉组合物
WO2023154705A1 (en) 2022-02-08 2023-08-17 United Therapeutics Corporation Treprostinil iloprost combination therapy
EP4516297A1 (en) 2022-04-29 2025-03-05 Zhaoke Pharmaceutical (Guangzhou) Co., Ltd Treprostinil soft mist inhalant
AU2024208919A1 (en) 2023-01-19 2025-07-17 United Therapeutics Corporation Treprostinil analogs

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4306075A (en) * 1980-03-28 1981-12-15 The Upjohn Company Composition and process
GB8814438D0 (en) 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
GB9300763D0 (en) * 1993-01-15 1993-03-03 Leo Pharm Prod Ltd Chemical compound
JP3215338B2 (ja) * 1995-12-15 2001-10-02 三菱化学株式会社 アミノベンゼンスルホン酸誘導体一水和物及びその製造方法
IT1282733B1 (it) * 1996-05-20 1998-03-31 Flarer S A Composizioni farmaceutiche contenenti ciclosporina ed un veicolante comprendente almeno un estere dell'acido alfa-glicerofosforico
US6441245B1 (en) 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
ATE262336T1 (de) 1997-11-14 2004-04-15 United Therapeutics Corp Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
US6017922A (en) * 1998-05-18 2000-01-25 U.S. Bioscience, Inc. Thermally stable trimetrexates and processes for producing the same
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
US6700025B2 (en) * 2001-01-05 2004-03-02 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
US6803386B2 (en) * 2002-01-16 2004-10-12 United Therapeutics Corporation Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer
US6756117B1 (en) 2002-12-20 2004-06-29 The United States Of America As Represented By The United States Department Of Energy Photonic polymer-blend structures and method for making
CA2526534C (en) * 2003-05-22 2011-07-12 United Therapeutics Corporation Compounds and methods for delivery of prostacyclin analogs
KR20050024121A (ko) * 2003-09-04 2005-03-10 동아제약주식회사 7-카르복시메틸옥시-3',4',5-트리메톡시 플라본.일수화물, 이의 제조방법 및 용도
DE602004028155D1 (de) * 2003-12-16 2010-08-26 United Therapeutics Corp Verwendung von treprostinil zur behandlung von ischämischen läsionen
WO2005058329A1 (en) * 2003-12-16 2005-06-30 United Therapeutics Corporation Use of treprostinil to improve kidney functions
JP2007532663A (ja) * 2004-04-12 2007-11-15 ユナイテッド セラピューティクス インコーポレイテッド ニューロパシー性の糖尿病性足潰瘍を治療するためのトレプロスチニルの使用
US8747897B2 (en) * 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
US20080200449A1 (en) 2006-05-15 2008-08-21 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler
US20090036465A1 (en) * 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
CA2678258A1 (en) * 2007-02-09 2008-08-14 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma
US20080280985A1 (en) 2007-03-27 2008-11-13 Scott Robert A D Methods and Compositions Using Certain Phenolic Derivatives for the Treatment of Diabetes
CN103274926B (zh) * 2007-12-17 2016-08-10 联合治疗公司 一种制备Remodulin中的活性成分曲前列素的改良方法

Also Published As

Publication number Publication date
KR20110010753A (ko) 2011-02-07
WO2009137066A1 (en) 2009-11-12
CA2723540C (en) 2016-01-05
ES2575565T3 (es) 2016-06-29
US20090281189A1 (en) 2009-11-12
CA2723540A1 (en) 2009-11-12
US8350079B2 (en) 2013-01-08
EP3002274A8 (en) 2016-07-13
EP2300408A1 (en) 2011-03-30
CN102015613A (zh) 2011-04-13
CN102015613B (zh) 2013-07-31
EP2300408B1 (en) 2016-04-13
JP2011519927A (ja) 2011-07-14
EP3002274A1 (en) 2016-04-06

Similar Documents

Publication Publication Date Title
JP6219016B2 (ja) トレプロスチニル一水和物
US7446116B2 (en) Montelukast amantadine salt
JP2022031717A (ja) オキサチアジン様化合物を作製する方法
KR102772428B1 (ko) 항미생물 화합물, 조성물, 및 그의 용도
CN112851666A (zh) 阿哌沙班与槲皮素共晶物及制备方法和其组合物与用途
US9504672B2 (en) Compositions and methods for treating or preventing pneumovirus infection and associated diseases
WO2016000568A1 (zh) 一种治疗痛风的化合物
KR20150046369A (ko) 데페라시록스 (ｉｃｌ６７０ａ)의 다형체 형태
CN118974047A (zh) 一种游离态plx5622晶型及其制备方法
WO2021139797A1 (zh) 恩曲替尼晶型及其制备方法
CN115487175A (zh) 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途
JP2007515430A (ja) アルコール及びケトン、及び／又はエステルの混合物である有機溶媒に塩を溶解し、そして溶媒を除去することにより非晶質アトルバスタチンへミ−カルシウムの調製方法
CN111518157B (zh) 一种雷公藤甲素衍生物及其制备方法和应用
UA52661C2 (uk) Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти
JP2019513151A (ja) カンプトテシン誘導体及びその使用
CN116874456B (zh) 贝前列素的前体药物
WO2025179296A1 (en) Crystalline forms of nu-3 and uses thereof
JP6871919B2 (ja) 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
CN117756798A (zh) 一种异丙托溴铵新晶体及其制备方法
WO2024260312A1 (zh) 多环氨基甲酰基吡啶酮衍生物的钠盐晶型及其制备方法和应用
CN102198135B (zh) 一种新型稳定的普卢利沙星盐酸盐在制备抗感染药物中的应用
JPS6245846B2 (enExample)
CN121358474A (zh) 取代的嘧啶酮和氮杂嘧啶酮化合物、其组合物及其用途
CN108623629B (zh) 一类治疗血栓相关性疾病的化合物、制备方法及其药物用途
CN119613310A (zh) 一种伊洛前列素衍生物及其制备方法和应用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140313

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140908

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140929

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150416

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150529

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150626

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170317

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170522

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20170727

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170927

R150 Certificate of patent or registration of utility model

Ref document number: 6219016

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250